AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18434839 — intervention group
Group type: COMPARATOR
Intervention: Silicone plug
Number of subjects: 36
Study 16505089 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (30,000 kIU) plus local anaesthetic injection and eccentric exercise
Number of subjects: 26
Study 16505089 — intervention group
Group type: COMPARATOR
Intervention: Saline (0.9%) plus local anaesthetic injections and eccentric exercises
Number of subjects: 26
Study 15144448 — intervention group
Group type: COMPARATOR
Intervention: Distilled water
Number of subjects: 30
Study 15144448 — intervention group
Group type: EXPERIMENTAL
Intervention: 17% EDTA
Number of subjects: 30
Study 15144448 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% sodium hypochlorite
Number of subjects: 30
Study 15144448 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonicated distilled water
Number of subjects: 30
Study 15144448 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonicated 17% EDTA
Number of subjects: 30
Study 15144448 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonicated 1% sodium hypochlorite
Number of subjects: 30
Study 11328224 — intervention group
Group type: EXPERIMENTAL
Intervention: Crinone 8% Vaginal Gel administered once daily in the morning for luteal phase support.
Number of subjects: 0
Study 11328224 — intervention group
Group type: COMPARATOR
Intervention: hCG for luteal phase support.
Number of subjects: 0
Study 11328224 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular progesterone for luteal phase support.
Number of subjects: 0
Study 9836101 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicobacter pylori positive patients
Number of subjects: 26
Study 9836101 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful eradication therapy
Number of subjects: 26
Study 9836101 — intervention group
Group type: COMPARATOR
Intervention: Unsuccessful eradication therapy
Number of subjects: 26
Study 9836101 — intervention group
Group type: COMPARATOR
Intervention: Helicobacter pylori negative patients
Number of subjects: 26
Study 7926137 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot leuprolide acetate (GnRH‐a) 7.5 mg with estrogen (0.625 mg/d) and progestin (Medroxyprogesterone acetate 10 mg/d)
Number of subjects: 10
Study 7926137 — intervention group
Group type: COMPARATOR
Intervention: Depot leuprolide acetate (GnRH‐a)
Number of subjects: 10
Study 2510660 — intervention group
Group type: EXPERIMENTAL
Intervention: labetalol (L)
Number of subjects: 42
Study 2510660 — intervention group
Group type: COMPARATOR
Intervention: captopril (C)
Number of subjects: 42
Study 963416 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial resection
Number of subjects: 126
Study 963416 — intervention group
Group type: COMPARATOR
Intervention: Simple closure
Number of subjects: 126
Study 31829833 — intervention group
Group type: EXPERIMENTAL
Intervention: Incisional negative-pressure wound therapy (NPWT)
Number of subjects: 223
Study 31484565 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose information program with follow-up email support and resources including an activity tracker (Fitbit) for 3 months and free trial class at the university sports facility
Number of subjects: 100
Study 31484565 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 100
Study 28269804 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training program (3 times a week for 11 weeks)
Number of subjects: 40
Study 28269804 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study 25455589 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS with neurocognitive training (PASAT)
Number of subjects: 33
Study 25455589 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS with neurocognitive training (PASAT)
Number of subjects: 33
Study 23642953 — intervention group
Group type: EXPERIMENTAL
Intervention: Needling with bi-directional rotation
Number of subjects: 53
Study 23642953 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep needling (2 cm)
Number of subjects: 53
Study 23642953 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial needling (0.3 cm)
Number of subjects: 53
Study 21081834 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin treatment (pravastatin 10 mg/day, fluvastatin 20 mg/day, pitavastatin 1 mg/day, atorvastatin 10 mg/day)
Number of subjects: 114
Study 21081834 — intervention group
Group type: COMPARATOR
Intervention: Control (non-statin-treated group with LDL-C < 140 mg/dL)
Number of subjects: 114
Study 19339325 — intervention group
Group type: EXPERIMENTAL
Intervention: ATM intervention (money management program)
Number of subjects: 85
Study 19339325 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (completion of a simple financial workbook)
Number of subjects: 85
Study 16762939 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium-enriched salt (experimental group)
Number of subjects: 1981
Study 16762939 — intervention group
Group type: COMPARATOR
Intervention: Regular salt (control group)
Number of subjects: 1981
Study 15686669 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural anesthesia (CSE)
Number of subjects: 20
Study 15686669 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (GA)
Number of subjects: 20
Study 11735093 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (850 mg twice daily) for 8 weeks
Number of subjects: 24
Study 9161941 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraexaminer measurements
Number of subjects: 50
Study 9161941 — intervention group
Group type: EXPERIMENTAL
Intervention: Interexaminer measurements
Number of subjects: 50
Study 8260300 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg
Number of subjects: 1257
Study 8260300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1257
Study 8260300 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium (neuromuscular blocker)
Number of subjects: 1257
Study 8260300 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcuronium (neuromuscular blocker)
Number of subjects: 1257
Study 8260300 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 1 mg
Number of subjects: 1257
Study 8260300 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 16 mg
Number of subjects: 1257
Study 2888937 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroleptics (chlorprothixene)
Number of subjects: 0
Study 2888937 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants (imipramine)
Number of subjects: 0
Study 2888937 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranquilizers (diazepam)
Number of subjects: 0
Study 2888937 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychostimulants (caffeine)
Number of subjects: 0
Study 2888937 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypoxidotics/nootropics (pyritinol)
Number of subjects: 0
Study 2888937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31436372 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (Actical activity monitor)
Number of subjects: 68
Study 31436372 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased physical activity
Number of subjects: 68
Study 29771080 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic corticosteroid monotherapy
Number of subjects: 98
Study 29771080 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic corticosteroid monotherapy
Number of subjects: 98
Study 29771080 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (IT plus systemic corticosteroid)
Number of subjects: 98
Study 29771080 — intervention group
Group type: COMPARATOR
Intervention: All groups combined (systemic, IT, and combination therapy)
Number of subjects: 98
Study 26845463 — intervention group
Group type: EXPERIMENTAL
Intervention: TB-specific quit smoking message delivered by doctors and a TB and smoking educational booklet and quit smoking guide
Number of subjects: 87
Study 26845463 — intervention group
Group type: COMPARATOR
Intervention: Ongoing cessation messages delivered by family members trained to be DOTS supporters
Number of subjects: 87
Study 26845463 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms of the study
Number of subjects: 87
Study 26845463 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 patients who shifted from heavy smoking to low-moderate levels post treatment
Number of subjects: 87
Study 24465955 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 glasses of sparkling white wine (30 g alcohol)
Number of subjects: 28
Study 24465955 — intervention group
Group type: COMPARATOR
Intervention: alcohol‐free sparkling white wine
Number of subjects: 28
Study 22183172 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg lamivudine (3TC) once daily for 10 days
Number of subjects: 24
Study 22183172 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg lamivudine (3TC) once daily for 10 days
Number of subjects: 24
Study 22183172 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg lamivudine-triphosphate (3TC-TP) once daily for 10 days
Number of subjects: 24
Study 22183172 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg lamivudine-triphosphate (3TC-TP) once daily for 10 days
Number of subjects: 24
Study 18812447 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil treatment
Number of subjects: 0
Study 17485597 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (Atacand, Astra Zeneca), 16 mg o.d. for 12 months
Number of subjects: 110
Study 17485597 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 16110036 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib (initial dose)
Number of subjects: 934
Study 11926853 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed, moderated, e-mail discussion group, along with a book and videotape about back pain
Number of subjects: 580
Study 11926853 — intervention group
Group type: COMPARATOR
Intervention: Non-health-related magazine subscription (control)
Number of subjects: 580
Study 9523246 — intervention group
Group type: EXPERIMENTAL
Intervention: Keyboard use in patients with RSI
Number of subjects: 0
Study 9523246 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprathreshold stimulation in patients with RSI
Number of subjects: 0
Study 9523246 — intervention group
Group type: COMPARATOR
Intervention: Control group (office workers)
Number of subjects: 0
Study 7657800 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin plus fat/heparin
Number of subjects: 0
Study 7657800 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin plus glycerol
Number of subjects: 0
Study 7657800 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 0
Study 7657800 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline plus fat/heparin
Number of subjects: 0
Study 7657800 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 0
Study 7657800 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin plus fat/heparin (euglycemic)
Number of subjects: 0
Study 7657800 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin (euglycemic)
Number of subjects: 0
Study 2663743 — intervention group
Group type: COMPARATOR
Intervention: Normal carbohydrate‐rich diet (N)
Number of subjects: 13
Study 2663743 — intervention group
Group type: EXPERIMENTAL
Intervention: High‐maltodextrin, low‐fructose beverage (Mf)
Number of subjects: 13
Study 779562 — intervention group
Group type: EXPERIMENTAL
Intervention: DM-prostaglandin E2 capsule (127 mug)
Number of subjects: 0
Study 779562 — intervention group
Group type: EXPERIMENTAL
Intervention: DM-prostaglandin E2 liquid (127 mug)
Number of subjects: 0
Study 779562 — intervention group
Group type: COMPARATOR
Intervention: DM-prostaglandin E2 capsule
Number of subjects: 0
Study 31650500 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative oxygen administration (SpO2 target of 90% with FreeO2 device)
Number of subjects: 30
Study 31650500 — intervention group
Group type: COMPARATOR
Intervention: Liberal oxygen administration (SpO2 target of ≥ 95% with manual titration)
Number of subjects: 30
Study 31650500 — intervention group
Group type: COMPARATOR
Intervention: Liberal oxygen administration in retainers
Number of subjects: 30
Study 31650500 — intervention group
Group type: COMPARATOR
Intervention: Liberal oxygen administration in non-retainers
Number of subjects: 30
Study 30640653 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-injection serratus block with L-bupivacaine 0.25% 30mL
Number of subjects: 60
Study 30640653 — intervention group
Group type: COMPARATOR
Intervention: Conventional analgesia
Number of subjects: 60
Study 29247513 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 90
Study 29247513 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 90
Study 26215480 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted temperature management (TTM) at 33°C
Number of subjects: 950
Study 26215480 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted temperature management (TTM) at 36°C
Number of subjects: 950
Study 26215480 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 950
Study 26215480 — intervention group
Group type: COMPARATOR
Intervention: Bystander defibrillation
Number of subjects: 950
Study 26215480 — intervention group
Group type: COMPARATOR
Intervention: Coronary angiography (CAG) and percutaneous coronary intervention (PCI) <24h after ROSC
Number of subjects: 950
Study 24142481 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month cycle ergometer exercise program supervised by primary care nurses (SE group; n = 46)
Number of subjects: 97
Study 24142481 — intervention group
Group type: COMPARATOR
Intervention: unsupervised walking program (UW group; n = 51)
Number of subjects: 97
Study 24142481 — intervention group
Group type: COMPARATOR
Intervention: Comparison between SE and UW groups
Number of subjects: 97
Study 22966864 — intervention group
Group type: EXPERIMENTAL
Intervention: HI estrogen phase
Number of subjects: 14
Study 22966864 — intervention group
Group type: COMPARATOR
Intervention: LO estrogen phase
Number of subjects: 14
Study 19620065 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin plus astragalus
Number of subjects: 84
Study 19620065 — intervention group
Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 84
Study 17725919 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Number of subjects: 20
Study 17725919 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 20
Study 15224060 — intervention group
Group type: EXPERIMENTAL
Intervention: Nickel sulfate
Number of subjects: 38
Study 15224060 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium dichromate
Number of subjects: 38
Study 15224060 — intervention group
Group type: EXPERIMENTAL
Intervention: Manganese chloride
Number of subjects: 38
Study 15224060 — intervention group
Group type: COMPARATOR
Intervention: Orthodontic appliances
Number of subjects: 38
Study 15876213 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime risk estimates of AD based on age, gender, family history, and Apolipoprotein E (APOE) genotype
Number of subjects: 149
Study 10569127 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance Interpersonal Psychotherapy (IPT)
Number of subjects: 25
Study 10569127 — intervention group
Group type: COMPARATOR
Intervention: Maintenance placebo, nortriptyline, or combination treatment
Number of subjects: 25
Study 8907290 — intervention group
Group type: EXPERIMENTAL
Intervention: gestodene/30ugEE
Number of subjects: 44
Study 8907290 — intervention group
Group type: EXPERIMENTAL
Intervention: desogestrel/30ugEE
Number of subjects: 44
Study 8907290 — intervention group
Group type: COMPARATOR
Intervention: aspirin
Number of subjects: 44
Study 8907290 — intervention group
Group type: COMPARATOR
Intervention: dazmegrel (UK38485)
Number of subjects: 44
Study 8907290 — intervention group
Group type: EXPERIMENTAL
Intervention: oral contraceptives
Number of subjects: 44
Study 1894034 — intervention group
Group type: EXPERIMENTAL
Intervention: Sperm prepared in human tubal fluid (HEPES buffer)
Number of subjects: 101
Study 1894034 — intervention group
Group type: COMPARATOR
Intervention: Sperm prepared in Ham's F-10 medium (bicarbonate buffer)
Number of subjects: 101
Study 6411878 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron treatment
Number of subjects: 21
Study 6411878 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 6411878 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron deficiency anemia
Number of subjects: 21
Study 30830494 — intervention group
Group type: EXPERIMENTAL
Intervention: Fotonovela
Number of subjects: 160
Study 30830494 — intervention group
Group type: EXPERIMENTAL
Intervention: Radionovela
Number of subjects: 160
Study 30830494 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital story
Number of subjects: 160
Study 30830494 — intervention group
Group type: COMPARATOR
Intervention: Attention control group (flu vaccination)
Number of subjects: 160
Study 30830494 — intervention group
Group type: EXPERIMENTAL
Intervention: All intervention arms
Number of subjects: 160
Study 29852043 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab for 9 weeks with docetaxel (80 or 100 mg/m2) followed by 3 cycles of fluorouracil, epirubicin, and cyclophosphamide
Number of subjects: 2174
Study 29852043 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab for 1 year with identical chemotherapy
Number of subjects: 2174
Study 27362552 — intervention group
Group type: EXPERIMENTAL
Intervention: Green placebo group
Number of subjects: 0
Study 27362552 — intervention group
Group type: EXPERIMENTAL
Intervention: Red placebo group
Number of subjects: 0
Study 27362552 — intervention group
Group type: EXPERIMENTAL
Intervention: Circle placebo group
Number of subjects: 0
Study 27362552 — intervention group
Group type: COMPARATOR
Intervention: Control groups
Number of subjects: 0
Study 24768615 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual tasking (performing a fluency task of listing items in a category)
Number of subjects: 20
Study 24768615 — intervention group
Group type: COMPARATOR
Intervention: Single-task condition (no dual tasking)
Number of subjects: 20
Study 24768615 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa (dopaminergic medication)
Number of subjects: 20
Study 22649263 — intervention group
Group type: EXPERIMENTAL
Intervention: Polydextrose (PDX; 21 g/d)
Number of subjects: 20
Study 22649263 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble corn fiber (SCF; 21 g/d)
Number of subjects: 20
Study 22649263 — intervention group
Group type: COMPARATOR
Intervention: No supplemental fiber (NFC)
Number of subjects: 20
Study 20181812 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium plus Vitamin D (1 g elemental Ca as carbonate plus 400 IU vitamin D(3)/d)
Number of subjects: 1259
Study 20181812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1259
Study 18614429 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg (Test)
Number of subjects: 14
Study 18614429 — intervention group
Group type: COMPARATOR
Intervention: Ciproxin 500 mg (Reference)
Number of subjects: 14
Study 16336424 — intervention group
Group type: COMPARATOR
Intervention: Cypher stent
Number of subjects: 11118
Study 16336424 — intervention group
Group type: COMPARATOR
Intervention: Taxus stent
Number of subjects: 11118
Study 16336424 — intervention group
Group type: COMPARATOR
Intervention: Endeavor stent
Number of subjects: 11118
Study 16336424 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-releasing stents without polymer
Number of subjects: 11118
Study 16336424 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel released from a polymer
Number of subjects: 11118
Study 16336424 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus released from a polymer
Number of subjects: 11118
Study 16336424 — intervention group
Group type: COMPARATOR
Intervention: Everolimus released from a polymer
Number of subjects: 11118
Study 16336424 — intervention group
Group type: COMPARATOR
Intervention: Biolimus A9 released from a polymer
Number of subjects: 11118
Study 16336424 — intervention group
Group type: COMPARATOR
Intervention: Zotarolimus released from a polymer
Number of subjects: 11118
Study 11919231 — intervention group
Group type: EXPERIMENTAL
Intervention: Early radiotherapy with concurrent chemotherapy (arm I)
Number of subjects: 274
Study 11919231 — intervention group
Group type: COMPARATOR
Intervention: Late radiotherapy with chemotherapy (arm II)
Number of subjects: 274
Study 10342082 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethindrone acetate (1 mg)/ethinyl estradiol (35 micrograms)
Number of subjects: 60
Study 10342082 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethindrone acetate (1 mg)/ethinyl estradiol (20 micrograms)
Number of subjects: 60
Study 10342082 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 smokers and 10 nonsmokers)
Number of subjects: 60
Study 7561329 — intervention group
Group type: EXPERIMENTAL
Intervention: Short perfusion group
Number of subjects: 26
Study 7561329 — intervention group
Group type: EXPERIMENTAL
Intervention: Long perfusion group
Number of subjects: 26
Study 1767368 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotary electric toothbrush
Number of subjects: 19
Study 1767368 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 19
Study 30996381 — intervention group
Group type: EXPERIMENTAL
Intervention: 3DP custom tray made by independent development chair-side system
Number of subjects: 15
Study 30996381 — intervention group
Group type: COMPARATOR
Intervention: Manually conventional method
Number of subjects: 15
Study 28448590 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium and coenzyme Q10 supplementation (200 μg Se/day as organic selenium yeast tablets and 200 mg/day of coenzyme Q10 capsules)
Number of subjects: 443
Study 28448590 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 443
Study 25372556 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet for 6 months
Number of subjects: 120
Study 25372556 — intervention group
Group type: COMPARATOR
Intervention: Healthy Eating diet for 6 months
Number of subjects: 120
Study 23435861 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim (n=74)
Number of subjects: 151
Study 23435861 — intervention group
Group type: COMPARATOR
Intervention: Filgrastim (n=76)
Number of subjects: 151
Study 20608950 — intervention group
Group type: EXPERIMENTAL
Intervention: Z-axis video observers
Number of subjects: 128
Study 20608950 — intervention group
Group type: COMPARATOR
Intervention: Still image observers
Number of subjects: 128